SAB Biotherapeutics (SABS) EBITDA Margin (2021 - 2024)
SAB Biotherapeutics' (SABS) quarterly EBITDA Margin came in at 8726.26% in Q4 2024, down 253836.0% YoY from N/an in Q1 2024, and down 125.08% on a QoQ basis from 3876.95% in Q2 2024.
Powered by 
Analysis
SAB Biotherapeutics (SABS) EBITDA Margin (2021 - 2024) Analysis & Trends
SAB Biotherapeutics (SABS) has 4 years of EBITDA Margin data on file, last reported at 8726.26% in Q4 2024.
- Quarterly EBITDA Margin fell 253836.0% year-over-year to 8726.26% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 3244.87% (down 154432.0% YoY) and the FY2024 annual result came in at 3244.87%, down 154432.0% from the prior year.
- EBITDA Margin slipped to 8726.26% in Q4 2024, from 3876.95% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 4.81% in Q1 2021 to a low of 8726.26% in Q4 2024.
- A 4-year average of 2007.32% and a median of 363.74% in 2022 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2023 — EBITDA Margin tumbled 747037 bps — and 2024, when it soared 369644 bps.
- Tracing SABS's EBITDA Margin over 4 years: stood at 66.41% in 2021, then plunged by 448 bps to 363.74% in 2022, then tumbled by 1601 bps to 6187.9% in 2023, then sank by 41 bps to 8726.26% in 2024.
- The last three EBITDA Margin figures came in at 8726.26% (Q4 2024), 3876.95% (Q2 2024), and 1205.9% (Q1 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | SAB Biotherapeutics | 296.68 Mn | 296.68 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | -8,726.26% |
| Jun 30, 2024 | -3,876.95% |
| Mar 31, 2024 | -1,205.90% |
| Dec 31, 2023 | -6,187.90% |
| Sep 30, 2023 | -420.00% |
| Jun 30, 2023 | -7,573.40% |
| Mar 31, 2023 | -1,273.79% |
| Dec 31, 2022 | -363.74% |
| Sep 30, 2022 | -217.49% |
| Jun 30, 2022 | -103.03% |
| Mar 31, 2022 | -56.83% |
| Dec 31, 2021 | -66.41% |
| Sep 30, 2021 | -27.18% |
| Jun 30, 2021 | -15.77% |
| Mar 31, 2021 | 4.81% |